Computational analysis demonstrates naringin's potential as an anti-adhesion agent against drug-resistant Helicobacter pylori, suggesting new therapeutic options.
Helicobacter pylori infection significantly damages the human stomach mucosa. This bacterium has established high levels of resistance to conventional drugs, necessitating alternative therapies. In this study, we evaluate, via a computational approach, the efficacy of 38 natural compounds as anti‐ H. pylori agents targeting six key proteins involved in survival, colonization, adhesion and drugs resistance. The result demonstrated that naringin is the better compounds which interact with the six target proteins (all in one time) displaying an XP GScore with urease (−9.78 kcal/mol), chorismate synthase (−10.93 kcal/mol), penicillin‐binding protein (−9.82 kcal/mol), HopQ type I (−6.77 kcal/mol), adhesin BabA (−8.68 kcal/mol), and adhesin SabA (−7.75 kcal/mol). RMSD, RMSF, and protein‐ligand contact plot analysis, confirmed the stability of naringin‐protein complexes during 100 ns MD simulation. Study of additional ligand interaction properties such as rGyr, SASA, intra‐HBs, MolSA, and PSA reinforced this stability. ADMET predictions indicated that naringin has poor gastrointestinal absorption and may serve as a substrate for P‐glycoprotein. Toxicity prediction also showed that naringin doesn't induce hepatotoxicity, neurotoxicity, cytotoxicity, carcinogenicity, immunotoxicity, mutagenicity, cytotoxicity but have a possible nephrotoxicity and cardiotoxicity. These results favor the use of naringin for the elaboration of an effective alternative therapeutic agents able to counteract adhesion and colonization of drug‐resistant H. pylori .
No takes yet. Share an insight, caveat, or question.
Kouidhi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: